Join
Live feed
·
PRReleasevia Quantisnow
AIM ImmunoTech Inc. logo

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

ByQuantisnow·Wall Street's wire, on your screen.
AIM· AIM ImmunoTech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AIM (AIM ImmunoTech Inc.) and more on Quantisnow.